Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
Recruiting · NCT05302037 · Registry updated 2024-11-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cancer, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm, refractory malignant neoplasm | Recruiting | Phase 1 | 2024-11-22 | NCT05302037 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CytoMed Therapeutics Pte Ltd | 1 |
| National University Hospital, Singapore | 120 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National University Hospital | Singapore | Singapore | 46 |